This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
==== Eva Kaili ==== Kaili denied any wrongdoing in the controversy. Her lawyers appeared on Greek TV stating that she "declares her innocence and that she has nothing to do with bribery from Qatar". Kaili's lawyers were also critical of her arrest as a "gross overreach of judicial power". They maintain that Kaili was in a state of shock, fear and confusion during her first interview and that she was not provided with an interpreter for the interview. According to her lawyers, it took a week for Kaili to be in "good enough psychological condition to be fully aware of what she was saying". Kaili reportedly felt "very troubled" and betrayed by her partner, Giorgi, according to her lawyers. Kaili has accused the Belgian authorities of "inhuman" behavior due to the Belgian authorities refusal to allow her to see her daughter in person or via Skype. Kaili said: "I am being tortured, this is so unfair that I cannot stand it, and I am breaking down. What is the problem with my little girl, why are they keeping her away from me?". The following day a three-hour meeting between Kaili and her daughter was authorised. The court decided on 16 February 2023 to keep Kaili in detention for another two months. Kaili had changed her Belgian lawyer from André Risopoulo to Sven Mary some time before the hearing. Mary had "represented one of the terrorists behind the 2015 Paris attacks". Kaili was released from pre-trial detention with an electronic bracelet on 14 April 2023 and, throughout the process, has continued to deny all charges against her.
==== Harvesting ==== The stem cells are typically harvested directly from the red marrow in the iliac crest, often under general anesthesia. The procedure is minimally invasive and does not require stitches afterwards. Depending on the donor's health and reaction to the procedure, the actual harvesting can be an outpatient procedure, or can require 1–2 days of recovery in the hospital. Another option is to administer certain drugs that stimulate the release of stem cells from the bone marrow into circulating blood. An intravenous catheter is inserted into the donor's arm, and the stem cells are then filtered out of the blood. This procedure is similar to that used in blood or platelet donation. In adults, bone marrow may also be taken from the sternum, while the tibia is often used when taking samples from infants. In newborns, stem cells may be retrieved from the umbilical cord.
Furthermore, the marked brocho-constriction produced by injections of histamine was not reversed by either l-synephrine or d,l-synephrine. In experiments with isolated sheep carotid artery, d-, l- and d,l-synephrine all showed some vasoconstrictor activity: l-synephrine was the most potent, producing strong contractions at a concentration of 1:10000. d-Synephrine was about 1/2 as potent as the l-isomer, but d,l-synephrine (which would have been expected to have a potency of 1/2 that of l-synephrine even if the d-isomer were completely inactive) did not produce significant and irregular contractions until a concentration of 1:2500had been reached, implying an inhibitory interaction between the two enantiomers. Qualitatively similar results were obtained in a rabbit ear preparation: 25 mg l-synephrine produced significant (50%) vasoconstriction, while the same concentration of d-synephrine elicited essentially no response. In contrast, d,l-synephrine did not produce any constriction up to 25 mg, but 25 – 50 mg caused a relaxation of the blood vessels, which again suggested that the d-isomer might be inhibiting the action of the l-isomer. Experiments on strips of rabbit duodenum showed that l-synephrine caused a modest reduction in contractions at a concentration of 1:17000, but that the effects of the d- and d,l- forms were much weaker. Racemic synephrine, given intramuscularly, or by instillation, was found to significantly reduce the inflammation caused by instillation of mustard oil into the eyes of rabbits.
=== Refugee Lodges of Hispaniola === In 1748, on Cuba's neighboring island of Hispaniola, Freemasonry in Haiti was established by the Grande Loge de France with the St. Jean de Jérusalem Ecossais (English: St. John of Jerusalem) in Cap-Français, Saint-Domingue (known today as Haiti). The second Haitain Lodge was chartered in 1765 at Los Cayos, called Les Frères Réunis No. 1 (English: Reunited Brothers). When the Haitian Revolution started, a mass exodus of French and Saint-Domingue Creole refugee emigres left Saint-Domingue and settled in Cuba. Freemasonry was allowed to continue for some time during the war in Saint-Domingue, where Huet de la Chapelle had become the Grand Master of the French Provincial Grand Loge in 1795, until a change in government forced the Haitian Lodges to flee the island and relocate elsewhere. As that conflict then spilled over the border into Santo Domingo (known today as the Dominican Republic), the Eastern half of that island also experienced a wave of emigration as Spaniards fled the colony. Most of these refugees from Saint-Domingue and Santo Domingo landed in the port towns of Oriente Province, especially Baracoa and Santiago de Cuba. In 1798, La Bénéfique Concorde was reestablished in Baracoa, La Persévérance was reestablished in Santiago de Cuba, and La Concorde L'Amitié relocated to Havana. The charters for these French Lodges, however, specifically limited their activities to Hispaniola.
Sources: en.wikipedia.org
Cleavage of proteins is an irreversible post-translational modification carried out by enzymes known as proteases. These proteases are often highly specific and cause hydrolysis of a limited number of peptide bonds within the target protein. The resulting shortened protein has an altered polypeptide chain with different amino acids at the start and end of the chain. This post-translational modification often alters the protein's function; the protein can be inactivated or activated by the cleavage and can display new biological activities.
"UNODC - Bulletin on Narcotics: The narcotic pepper - The chemistry and pharmacology of Piper methysticum and related species". United Nations Office on Drugs and Crime. 1973. pp. Issue 2. Retrieved 19 February 2014. Kava ban documents Piper methysticum information from the Hawaiian Ecosystems at Risk project (HEAR) "Kava" . Encyclopædia Britannica. Vol. 14 (9th ed.). 1882.
Henderson would be executed in the electric chair in the Florida State Prison on April 21, 1993, fourteen months after his arrest. Serial killer David Bullock, suspected in having killed six people with a .38 caliber revolver in one month, from December 5 to January 4, was arrested by the New York Police Department. He would plead guilty to all charges on October 26, commenting "I was in the Christmas spirit. It made me happy." Bullock would be sentenced to 150 years imprisonment. The popular Tamil language film Pokkiri Raja (King of Rogues), an action comedy produced by AVM Saravanan, directed by S. P. Muthuraman and starring Rajinikanth (Shivaji Rao Gaikwad) in two roles, was released in India by Ananda Films. Born: Ireti Osayemi, Nigerian film actress and 2017 Best of Nollywood Award winner for best supporting actress in Ojo Meta (Three Days); in Lagos State Joe Dunthorne, Welsh novelist known for Submarine; in Swansea
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.